In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62 ...
In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62 ...
According to the company's Chairman and CEO, Samarth Kulkarni, Ph.D., CRISPR Therapeutics aims to build on the successful launch of CASGEVY®, expanding its portfolio to include treatments for ...
a strong balance sheet and an organizational foundation to drive our pipeline forward,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Building on ...
said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across ...
a strong balance sheet and an organizational foundation to drive our pipeline forward,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. "Building on the ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback